MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, which trades under the ticker HLXA, is a clinical-stage biopharmaceutical company focused on inflammatory diseases, with its lead asset sonelokimab targeting the IL-17A/F pathway. The company entered the public markets through its merger with Helix Acquisition Corp, a healthcare-focused blank-check vehicle sponsored by Helix Acquisition Holdings LLC that completed its IPO in 2021. The business combination closed in early 2022, and MoonLake has since operated as a Nasdaq-listed entity advancing its nanobody pipeline. The June 2024 8-K filing reflects continued post-merger disclosure obligations under SEC reporting requirements. For full filing history, pipeline milestones, and SPAC deal analytics on HLXA, sign up for SpacDesk at spacdesk.com.